ZW 251
Alternative Names: ZW-251Latest Information Update: 15 Jan 2024
At a glance
- Originator Zymeworks
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 04 Jan 2024 Zymeworks announces intention to submit an IND application for Liver cancer in 2025
- 04 Jan 2024 Zymeworks plans a first in human clinical trial for Liver cancer in 2025
- 23 Apr 2023 Pharmacodynamics data from preclinical study in Liver cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)